Abstract: This invention relates to a heterocyclic compound of the formula wherein a group of the formula: is a group of the formula X is O, S or N-R5, R1 is lower alkyl, etc., R5 is hydrogen, lower alkyl, etc., R2 is hydrogen, halogen, lower alkyl, etc., R3 is halogen, lower alkyl, etc., R4 is amino optionally having suitable substituent(s), and A is lower alkylene, and a salt thereof, to processes for preparation thereof, and to a pharmaceutical composition comprising the same for the prevention and/or the treatment of bradykinin or its analogues mediated diseases in human being or animals.

Abstract: The invention relates to a pharmaceutical composition for ophthalmic administration comprising a compound of the formula: wherein X1, X2, X3, R1, R2, R3, R4, R5, Q and A are as defined in the disclosure. This invention also relates to methods of using the pharmaceutical composition in the prevention and/or treatment of bradykinin or its analogues mediated diseases in the eye, such as allergy, inflammation and pain of the eye.

Abstract: This invention relates to a heterocyclic compound of the formula: ##STR1## wherein a group of the formula: ##STR2## is a group of the formula: ##STR3## etc., X is O, S or N--R.sup.5,R.sup.1 is lower alkyl, etc.,R.sup.5 is hydrogen, lower alkyl, etc.,R.sup.2 is hydrogen, halogen, lower alkyl, etc.,R.sup.3 is halogen, lower alkyl, etc.,R.sup.4 is amino optionally having suitable substituent(s), andA is lower alkylene,and a salt thereof, to processes for preparation thereof, and to a pharmaceutical composition comprising the same for the prevention and/or the treatment of bradykinin or its analogues mediated diseases in human being or animals.

Abstract: A compound of the formula: ##STR1## wherein R.sup.1 is lower alkyl,R.sup.2 is hydrogen, lower alkyl or a heterocyclic group,R.sup.3 is hydrogen, lower alkyl or halogen,R.sup.4 is lower alkyl or halogen,R.sup.5 is nitro or amino substituted with substituent(s) selected from the group consisting of lower alkyl and acyl, andA is lower alkylene.

Abstract: Described are a vibration actively reducing apparatus and a method for identifying a transfer function in the vibration actively reducing apparatus. An identification signal which is a quantization of at least one sinusoidal wave is supplied from a controller of the vibration actively reducing apparatus to a controlled vibration source in synchronization with a predetermined output sampling clock (SCo) to develop an identification vibration therefrom. The controller reads a residual vibration signal from a residual vibration detector of the actively reducing apparatus in synchronization with a predetermined input sampling clock (SCi). After read of the residual vibration signal as a time series data for each frequency, an FFT calculation is carried out for each time series data to extract a frequency component of the original sinusoidal wave.

Abstract: This invention relates to a quinoline compound of the formula: ##STR1## wherein R.sup.1 is a pyridyl group or aryl, each of which may be substituted with suitable substituent(s),A is --COHN-- or --NHCO--,n is an integer of 0 or 1, and ##STR2## is a group of the formula: ##STR3## In which R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6 and R.sup.7 are as defined,and pharmaceutically acceptable salt thereof, to processes for preparation thereof, to a pharmaceutical composition comprising the same, and to a method for the prevention and/or the treatment of bone diseases caused by abnormal bone metabolism in human being or animals.

Abstract: This invention relates to a compound of the formula: ##STR1## wherein Z is a group of the formula: ##STR2## in which X.sup.1 is N or C--R.sup.1,X.sup.2 is N or C--R.sup.9,X.sup.3 is N or C--R.sup.2,R.sup.1 is lower alkyl,R.sup.2 is hydrogen, lower alkyl, etc.,R.sup.9 is hydrogen or lower alkyl,R.sup.3 is halogen, etc.,R.sup.4 is halogen, etc.,R.sup.5 is a group of the formula: ##STR3## A is lower alkylene, and Y is O, etc.,and pharmaceutically acceptable salts thereof, to processes for preparation thereof, to a pharmaceutical composition comprising the same, and to methods to using the same therapeutically in the prevention and/or the treatment of bradykinin or its analogues mediated diseases in human being or animals.

Abstract: Described is a vibration isolator of a vibration actively reducing apparatus which achieves a more accurate detection of a residual vibration by means of a load sensor after an interference of a controlled vibration developed from a controlled vibration source constituting the vibration isolator against a vibration developed and transmitted from a vibration source such as a vehicular engine. In the vibration isolator, all vibration forces developed and transmitted from the vibration source are once concentrated onto a predetermined rigidity member such as a yoke of an electromagnetic actuator constituting the controlled vibration source and the load sensor is installed between the predetermined rigidity member and a lid member of the vibration isolator coupled to a supporting base member attached onto, for example, a vehicle body.

Abstract: A compound of the formula: ##STR1## wherein --X.sup.3 .dbd.X.sup.2 --X.sup.1 .dbd.N-- is a group of the formula: ##STR2## R.sup.1 is hydrogen or halogen, R.sup.2 is halogen,R.sup.3 is hydrogen, nitro, amino optionally having at least one substituent or a heterocyclic group optionally having at least one substituent,R.sup.4 and R.sup.5 are each hydrogen, or halogen,R.sup.6 and R.sup.8 are each hydrogen, halogen, lower alkyl, hydroxy, lower alkylthio, amino optionally substituted with lower alkyl, or lower alkoxy optionally substituted with a substituent selected from the group consisting of hydroxy, lower alkoxy, amino, lower alkylamino and aryl optionally substituted with lower alkoxy,R.sup.7 is hydrogen or lower alkyl,A is lower alkylene, andQ is O or N--R.sup.9 is hydrogen or acyl,provided that R.sup.3 is not hydrogen when X.sup.1 is C--R.sup.6, in which R.sup.6 is hydrogen, andpharmaceutically acceptable salts thereof.

Abstract: In apparatus and method for actively reducing a periodic vibration and/or noise, a divergence determinator is provided in which a presence or absence of a higher order divergence of a control of the reduction of the periodic vibration and/or noise is determined on the basis of a sum of two sampled values of at least one of either a drive signal y or a residual wave (vibration or noise) signal e, phases of the two sampled values being mutually deviated from each other by an approximately half period of a fundamental order of the corresponding drive or residual wave signal.

Abstract: A vibration control apparatus for a vehicle equipped with a power unit and a vehicle body is comprised of an active engine mount disposed between the power unit and the vehicle body. A controller is connected to a vehicle body vibration detector, a passenger compartment vibration detector and a drive force detector. The vehicle body vibration detector detects a vibration transmitted from the power unit to the vehicle body through the active engine mount. The passenger compartment vibration detector detects a vibration of a member defining a passenger compartment of the vehicle. The drive force detector detects as to whether driving force of the power unit is transmitted to driving wheels. The controller controls the active engine mount to reduce the passenger compartment vibration when the driving force is transmitted to the driving wheels and to reduce the vehicle body vibration when the driving force is not transmitted to the driving wheels.

Abstract: The invention relates to bradykinin antagonists of the formula: ##STR1## wherein R.sup.1 is halogen,R.sup.2 and R.sup.3 are each hydrogen, lower alkyl, halo(lower)alkyl or acyl,R.sup.4 is aryl having suitable substituent(s), or a heterocyclic group optionally having suitable substituent(s),Q is O or N--R.sup.11, in which R.sup.11 is hydrogen or acyl, andA is lower alkylene,and pharmaceutically acceptable salts thereof.

Abstract: A compound of the formula: ##STR1## or its salt is prepared by reacting a compound of the formula: ##STR2## with a compound of the formula: ##STR3## Wherein the variables are all defined in claim 1.

Abstract: A control type vibro-isolating support includes a pulse signal generator for generating reference signals x, which represent the state of the vibration being generated by an engine. An acceleration sensor detects residual vibration on the support member side, and generates a residual vibration signal e. A controller is supplied with the reference signals x and residual vibration signal e. On the basis of the reference signals x and residual vibration signal e and in accordance with, for example, synchronous filtered X LMS algorithm, the controller generates a drive signal y so as to lower the vibration level on the member side. An engine mount is interposed between the engine and the member, and has an electromagnetic actuator. The drive circuit for the actuator is supplied with the drive signal y.

Abstract: The invention relates to novel bradykinin antagonists of the formula: ##STR1## wherein R.sup.1 is halogen,R.sup.2 and R.sup.3 are each hydrogen, lower alkyl, halo(lower)alkyl or acyl,R.sup.4 is aryl having suitable substituent(s), or a heterocyclic group optionally having suitable substituent(s),Q is O or N--R.sup.11, in which R.sup.11 is hydrogen or acyl, andA is lower alkylene,and pharmaceutically acceptable salts thereof.

Abstract: This invention relates to new heterocyclic compounds and pharmaceutically acceptable salts thereof. More particularly, this invention relates to new heterocyclic compounds and salts thereof which display bradykinin antagonist activity, to processes for preparing these compounds, to a pharmaceutical composition comprising these compounds, and to methods of using same in the prevention and/or the treatment of bradykinin- or bradykinin analogue-mediated diseases such as allergy, inflammation, autoimmune disease, shock, pain, or the like, in human beings or in animals.

Abstract: This invention related to compounds of the formula ##STR1## wherein the radicals are as defined in the claims. The compounds are angiotensin II antagonists useful in treating hypertension, etc.

Abstract: The invention relates to compounds of the formula ##STR1## wherein ##STR2## represents a condensed or uncondensed imidazolyl ring and the rest of the variables are as defined in the specification. They are angiotensin II antagonists useful for treating hypertension, etc..

Abstract: The invention concerns compounds of the formula ##STR1## represents a condensed or uncondensed imidazolyl ring and the rest of the variables are defined in the specification. They are angiotensin II antagonists useful for treating hypertension, etc.